TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24136321

Group type: EXPERIMENTAL
Intervention: Split thickness skin graft (STSG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no STSG)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 22521460

Group type: EXPERIMENTAL
Intervention: Cesarean delivery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vaginal delivery
Number of subjects: 200
Study: 21338187

Group type: EXPERIMENTAL
Intervention: Weekly GCSF therapy before weekly craniospinal radiotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group without GCSF prophylaxis
Number of subjects: 40
Study: 17436011

Group type: EXPERIMENTAL
Intervention: Videoscopic splanchnicectomy (VSPL)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (symptomatic treatment)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patients treated with opioids before surgery
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 90
Study: 16638030

Group type: EXPERIMENTAL
Intervention: Subcutaneous sterile water injection (0.5 mL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 100
Study: 12785471

Group type: COMPARATOR
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP) alone (N=214)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: CBASP in combination with nefazodone (N=217)
Number of subjects: 431

Group type: COMPARATOR
Intervention: CBASP alone (N=214)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: CBASP (both alone and with medication)
Number of subjects: 431
Study: 10958222

Group type: EXPERIMENTAL
Intervention: Serum beta2-microglobulin levels in patients with HCC
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Correlation of beta2-microglobulin with interleukin-6 (IL-6)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Correlation of beta2-microglobulin with alpha-fetoprotein
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Correlation of beta2-microglobulin with tumour size
Number of subjects: 120
Study: 9008516

Group type: EXPERIMENTAL
Intervention: High plasma valproate group (80 to 150 micrograms/mL)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Low plasma valproate group (25 to 50 micrograms/mL)
Number of subjects: 143
Study: 8474315

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 24 IU
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 3089411

Group type: EXPERIMENTAL
Intervention: Haemoccult test offered during a routine consultation
Number of subjects: 25852

Group type: COMPARATOR
Intervention: Other methods of invitation (letter with test, letter with appointment, educational booklet)
Number of subjects: 25852

Group type: COMPARATOR
Intervention: Farnborough screening program
Number of subjects: 25852

Group type: COMPARATOR
Intervention: Screening results
Number of subjects: 25852
Study: 29496251

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 6717

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 6717
Study: 27189297

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1 μg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 2 μg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous dexmedetomidine 1 μg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 100
Study: 25038306

Group type: EXPERIMENTAL
Intervention: Intensive intervention (LDL-C target <100 mg/dL, switching ART if needed, low-dose aspirin)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard intervention (LDL-C target <130 mg/dL)
Number of subjects: 47
Study: 23226979

Group type: EXPERIMENTAL
Intervention: Oral hyaluronic acid (HA) 200 mg once a day for 12 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19819529

Group type: EXPERIMENTAL
Intervention: JJ-ureteral stent with antireflux-membrane valve
Number of subjects: 133

Group type: COMPARATOR
Intervention: JJ-ureteral stent without valve
Number of subjects: 133
Study: 17505450

Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Vaginal hysterectomy
Number of subjects: 400
Study: 15551351

Group type: EXPERIMENTAL
Intervention: Sertraline (50-150 mg)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study: 12046308

Group type: EXPERIMENTAL
Intervention: Trabeculectomy in juvenile glaucoma group (Group I)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Juvenile glaucoma suspect group (Group II)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (Group III)
Number of subjects: 32
Study: 7878390

Group type: EXPERIMENTAL
Intervention: Desmopressin spray
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 3067322

Group type: EXPERIMENTAL
Intervention: 100 micrograms/kg ivermectin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 150 micrograms/kg ivermectin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 micrograms/kg ivermectin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30912578

Group type: EXPERIMENTAL
Intervention: Corrected FFR (cFFR) for distal left anterior descending (LAD) artery
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Corrected FFR (cFFR) for distal circumflex (Cx) artery
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Corrected FFR (cFFR) for distal right coronary artery-posterior left ventricular artery (RCA-PLV)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Corrected FFR (cFFR) for distal RCA-posterior descending artery (PDA)
Number of subjects: 100
Study: 31640455

Group type: EXPERIMENTAL
Intervention: Lotus valve
Number of subjects: 912

Group type: COMPARATOR
Intervention: CoreValve
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Pacemaker dependent
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Not pacemaker dependent
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Pacemaker dependency
Number of subjects: 912
Study: 28935140

Group type: EXPERIMENTAL
Intervention: d-Allulose (5 g)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Aspartame (10 mg)
Number of subjects: 13
Study: 25451582

Group type: EXPERIMENTAL
Intervention: Advergame promoting energy-dense snacks
Number of subjects: 92

Group type: COMPARATOR
Intervention: Advergame promoting nonfood products
Number of subjects: 92
Study: 24088976

Group type: EXPERIMENTAL
Intervention: LPS-Flex mobile
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: LPS-Flex fixed
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: LPS mobile
Number of subjects: 74

Group type: COMPARATOR
Intervention: LPS fixed
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Postoperative flexion
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Knee Society Score
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Knee Society Score function
Number of subjects: 74
Study: 22117659

Group type: EXPERIMENTAL
Intervention: Vitamin D‐3 supplementation of 400 IU/day
Number of subjects: 52

Group type: COMPARATOR
Intervention: Unsupplemented group
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Vitamin D‐3 supplementation
Number of subjects: 52
Study: 19329824

Group type: EXPERIMENTAL
Intervention: FAS/Partial FAS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Static Encephalopathy/Alcohol Exposed (SE/AE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neurobehavioral Disorder/Alcohol Exposed (ND/AE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy peers with no prenatal alcohol exposure
Number of subjects: 0
Study: 16775813

Group type: EXPERIMENTAL
Intervention: Crude stevioside 3.75 mg/kg/day (7 weeks), 7.5 mg/kg/day (11 weeks), 15.0 mg/kg/day (6 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15286068

Group type: EXPERIMENTAL
Intervention: Medication management training for community mental health nurses
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 120
Study: 11736893

Group type: EXPERIMENTAL
Intervention: In vitro cytotoxicity model using HaCaT cells with various irritants (100 µL of 20 mmol L(‐1) aqueous solution)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vivo irritation potential in humans after 24-hour application of the same compounds
Number of subjects: 0
Study: 9403904

Group type: EXPERIMENTAL
Intervention: Multi-disciplinary community team
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional psychiatric service
Number of subjects: 0
Study: 8277130

Group type: EXPERIMENTAL
Intervention: Self-efficacy interventions
Number of subjects: 2524

Group type: EXPERIMENTAL
Intervention: Socioeconomic status
Number of subjects: 2524
Study: 3147905

Group type: EXPERIMENTAL
Intervention: Cholestyramine (12 g orally)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cholestyramine (3 x 12 g daily for 4 weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cholestyramine (acute and chronic administration)
Number of subjects: 10
Study: 30095504

Group type: EXPERIMENTAL
Intervention: Short-duration isometric knee extension loading (24 sets of 10 seconds)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Long-duration isometric knee extension loading (6 sets of 40 seconds)
Number of subjects: 16
Study: 31375043

Group type: EXPERIMENTAL
Intervention: Hands-Free Single Crutch (HFSC)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard Axillary Crutches (SACs)
Number of subjects: 44
Study: 28425029

Group type: COMPARATOR
Intervention: AAFP 500 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: AAFP 100 mg, 200 mg, 400 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: AAFP 125 mg, 500 mg, 625 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: OAA 1000 mg
Number of subjects: 56
Study: 25318481

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg BID
Number of subjects: 15526

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg BID
Number of subjects: 15526

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (both doses combined)
Number of subjects: 15526

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 15526

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15526
Study: 23551798

Group type: EXPERIMENTAL
Intervention: Group assertiveness training (12 sessions)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Supportive control group
Number of subjects: 74
Study: 21114586

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 242

Group type: COMPARATOR
Intervention: PEG-interferon
Number of subjects: 242
Study: 18926940

Group type: EXPERIMENTAL
Intervention: Alkaline mineral water (water B) rich in bicarbonate (per litre: 547 mg Ca, 2172 mg HCO(3)(‐), 9 mg SO(4)(‐), PRAL ‐11.2 mEq)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acid calcium-rich water (water A) (per litre: 520 mg Ca, 291 mg HCO(3)(‐), 1160 mg SO(4)(‐), PRAL +9.2 mEq)
Number of subjects: 30
Study: 17710657

Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no amifostine)
Number of subjects: 28
Study: 15001730

Group type: EXPERIMENTAL
Intervention: olanzapine plus divalproex
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: risperidone plus divalproex
Number of subjects: 249

Group type: COMPARATOR
Intervention: olanzapine plus placebo
Number of subjects: 249

Group type: COMPARATOR
Intervention: risperidone plus placebo
Number of subjects: 249
Study: 11341350

Group type: EXPERIMENTAL
Intervention: Interventions promoting mammography screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interventions targeting older women (minimum age, 50-65 years)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interventions set in clinics
Number of subjects: 0
Study: 9635220

Group type: EXPERIMENTAL
Intervention: Preventive intervention aimed at reducing aggressive, disruptive behavior in first and second grades.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: First grade boys' own aggressive behavior.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: First grade boys' poverty level.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: First grade girls' own aggressive behavior.
Number of subjects: 19
Study: 7942080

Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy (HRT)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Oophorectomy (BSO) without HRT
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Oophorectomy (BSO) with HRT
Number of subjects: 95

Group type: COMPARATOR
Intervention: Ovaries preserved and not receiving HRT
Number of subjects: 95

Group type: COMPARATOR
Intervention: Continuous venous blood sampling before and after surgery
Number of subjects: 95
Study: 2884551

Group type: COMPARATOR
Intervention: 0 glasses/d (control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2 glasses/d
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4 glasses/d
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 14 glasses (binge drinking)
Number of subjects: 12
Study: 29417987

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 94
Study: 30151819

Group type: EXPERIMENTAL
Intervention: Extended anticoagulation with vitamin K antagonists
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Low-risk group
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Moderate-risk group
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: High-risk group
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Clinical score
Number of subjects: 743
Study: 26574485

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control
Number of subjects: 198
Study: 23708468

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) for one month
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) for two months
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) for four months
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard psychosocial treatment
Number of subjects: 118
Study: 21592879

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 10/320 mg
Number of subjects: 834

Group type: COMPARATOR
Intervention: Monotherapies (amlodipine 10 mg, valsartan 160 or 320 mg)
Number of subjects: 834

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Combination therapy (Amlodipine/valsartan)
Number of subjects: 834
Study: 18355511

Group type: EXPERIMENTAL
Intervention: Modified Cox mini-Maze procedure using unipolar and bipolar radiofrequency systems
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Modified Cox mini-Maze procedure
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cox Maze III control group
Number of subjects: 45
Study: 17030755

Group type: EXPERIMENTAL
Intervention: Arterial spin labeling (ASL) MRI in patients with FTD
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Frontal perfusion added to gray matter (GM) atrophy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Parietal perfusion added to GM atrophy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combining frontal and parietal lobe perfusion
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cognitively normal (CN) subjects
Number of subjects: 70
Study: 12745039

Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU) 400 mg
Number of subjects: 74

Group type: COMPARATOR
Intervention: Acetaminophen (ACET) 1000 mg
Number of subjects: 74
Study: 10857171

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) mapping
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elective lymph node dissection (ELND)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic adjuvant therapy
Number of subjects: 0
Study: 8623187

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) - enoxaparin 40 mg/day
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 1452959

Group type: EXPERIMENTAL
Intervention: Effective Patient Teaching course
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no course)
Number of subjects: 30
Study: 3006619

Group type: EXPERIMENTAL
Intervention: Enalapril (EN) 20 mg once-a-day
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 104
Study: 31506396

Group type: COMPARATOR
Intervention: Ropinirole hydrochloride
Number of subjects: 0
Study: 29757924

Group type: EXPERIMENTAL
Intervention: Ketamine infusion (40 μg kg min over 5 min followed by 2.5 μg kg min)
Number of subjects: 121

Group type: COMPARATOR
Intervention: 0.9% saline infusion (control group)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 121
Study: 25749689

Group type: EXPERIMENTAL
Intervention: Hybrid (ALIF at L5/S1 with total disc replacement at L4/5)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Fusion (2-level circumferential fusion with TLIF)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Hybrid
Number of subjects: 62

Group type: COMPARATOR
Intervention: Fusion
Number of subjects: 62
Study: 24287940

Group type: EXPERIMENTAL
Intervention: DEP 75 mg
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: FEN 25 mg
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: MZD 2 mg
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: SIB 15 mg
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: FXT 20 mg
Number of subjects: 174

Group type: COMPARATOR
Intervention: PCB
Number of subjects: 174
Study: 22408266

Group type: EXPERIMENTAL
Intervention: Discontinued antidepressant treatment (63 patients)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Continuation of antidepressant treatment (68 patients)
Number of subjects: 128
Study: 20814318

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 72
Study: 17728419

Group type: EXPERIMENTAL
Intervention: Adjunctive antidepressant use
Number of subjects: 335

Group type: COMPARATOR
Intervention: Mood stabilizers alone (Control)
Number of subjects: 335
Study: 15056426

Group type: EXPERIMENTAL
Intervention: Early resting myocardial perfusion gated-SPECT
Number of subjects: 222

Group type: COMPARATOR
Intervention: Conventional management without gated-SPECT
Number of subjects: 222
Study: 11703993

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 4632

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 4632
Study: 9881888

Group type: EXPERIMENTAL
Intervention: Glucose (25, 50, 100 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sucrose (25, 50, 100 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fructose (25, 50 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: White bread (25, 50, 100 g carbohydrate)
Number of subjects: 8
Study: 8025071

Group type: EXPERIMENTAL
Intervention: 2% nedocromil sodium
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 2% sodium cromoglycate
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 2554344

Group type: EXPERIMENTAL
Intervention: Breathhold duration of 0 seconds
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Breathhold duration of 10 seconds
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Breathhold duration of 20 seconds
Number of subjects: 8
Study: 1252350

Group type: EXPERIMENTAL
Intervention: White soft paraffin
Number of subjects: 0
Study: 31252293

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy after extrapleural pneumonectomy
Number of subjects: 0
Study: 28532935

Group type: EXPERIMENTAL
Intervention: Intraoperative computer‐assisted registration (Group 1)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Intraoperative aberrometry (Group 2)
Number of subjects: 52
Study: 24646076

Group type: EXPERIMENTAL
Intervention: Beetroot juice (0.07 mmol NO(3)(‐) /kg body weight/day; BR, n=11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control drink (CON, n=11)
Number of subjects: 22
Study: 22672229

Group type: EXPERIMENTAL
Intervention: Bipolar TURP
Number of subjects: 286

Group type: COMPARATOR
Intervention: Monopolar TURP
Number of subjects: 286
Study: 21719896

Group type: EXPERIMENTAL
Intervention: Common TRPA1 haplotype defined by 1 missense and 10 intronic single nucleotide polymorphisms.
Number of subjects: 0
Study: 19200422

Group type: EXPERIMENTAL
Intervention: Bipolar I disorder
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Schizophrenia
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Delusional disorder
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Major depressive disorder (MDD), severe, with psychotic features
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Brief psychotic disorder
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Psychotic disorder not otherwise specified (NOS)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Schizophreniform disorder
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Diagnostic changes
Number of subjects: 500
Study: 15615749

Group type: EXPERIMENTAL
Intervention: Surgical induction of chorioretinal venous anastomosis (standard vitrectomy with choroidal incisions and Mersilene suture insertion)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Surgical induction of chorioretinal venous anastomosis
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no surgery)
Number of subjects: 28
Study: 12453326

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 425 mg/m2 with low-dose folinic acid (FA) 20 mg/m2, administered as a rapid bolus intravenous injection for 5 days every 4-5 weeks
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) with low-dose folinic acid (FA)
Number of subjects: 412
Study: 10445530

Group type: EXPERIMENTAL
Intervention: Erythromycin (3 mg/kg) administered intravenously over 15 min before consumption of 300 g minced beef and 150 ml water.
Number of subjects: 6